Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172680 | 0.78 | ADH1B (0.31) | ADH1BADH1CADH1A | |
| SCHEMBL24133132 | 0.78 | ADH1B (0.31) | ADH1BADH1CADH1A | |
| SCHEMBL172672 | 0.73 | ADH1B (0.35) | ADH1BADH1CADH1A | |
| SCHEMBL19910925 | 0.73 | ADH1B (0.35) | ADH1BADH1CADH1A | |
| SCHEMBL18327442 | 0.71 | — | — | |
| SCHEMBL16234248 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL19895467 | 0.71 | ADH1B (0.33) | ADH1BADH1CADH1A | |
| Hydrochloric Acid SCHEMBL19895466 | 0.71 | ADH1B (0.33) | ADH1BADH1CADH1A | |
| SCHEMBL4667011 | 0.71 | ADH1B (0.33) | ADH1BADH1CADH1A | |
| SCHEMBL7777047 | 0.71 | LMNA (0.38) | ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200306376-A1 | COMPOSITIONS AND METHODS FOR TARGETED TUMOR IMMUNOTHERAPY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306376-A1 | COMPOSITIONS AND METHODS FOR TARGETED TUMOR IMMUNOTHERAPY | CD47, CD274, CD74 | ADH1B 3539/4885ADH1C 4508/4885ADH1A 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.